A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse

BACKGROUND: Recombinant human immunoglobulin M22 (rHIgM22) has promoted remyelination in animal models and was well tolerated in people with clinically stable multiple sclerosis. OBJECTIVE: Safety/tolerability of a single rHIgM22 dose was investigated following an acute relapse and to determine whet...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenberg, Benjamin M., Bowen, James D., Alvarez, Enrique, Rodriguez, Moses, Caggiano, Anthony O., Warrington, Arthur E., Zhao, Ping, Eisen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052243/
https://www.ncbi.nlm.nih.gov/pubmed/35496758
http://dx.doi.org/10.1177/20552173221091475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052243/
https://www.ncbi.nlm.nih.gov/pubmed/35496758
http://dx.doi.org/10.1177/20552173221091475

Ejemplares similares